Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers
businesswire.com
news
2022-10-20 00:00:00

October 20, 2022 09:00 AM Eastern Daylight Time SANTA MONICA, Calif. & MENLO PARK, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD) and Refuge Biotechnologies, Inc. ('Refuge'), today announced that Kite has entered into an exclusive, worldwide license agreement with Refuge, a synthetic biology company for cancer immunotherapy, for exclusive rights to utilize Refuge's proprietary gene expression platform to develop potential treatments for blood cancers.



Refuge's proprietary platform is a synthetic biology system that utilizes an expression modulation strategy to repress or activate transcription of target genes.
